title: Advances in HSP27 and HSP90-targeting strategies for glioblastoma.
abstract: Glioblastoma (GBM) is the most common and malignant primary brain tumor in adults. There is a critical need for novel strategies to abolish the molecular mechanisms that support GBM growth, invasion and treatment resistance. The heat shock proteins, HSP27 and HSP90, serve these pivotal roles in tumor cells and have been identified as effective targets for developing therapeutics. Natural and synthetic inhibitors have been evaluated in clinical trials for several forms of systemic cancer but none as yet for GBM. This topic review summarizes the current preclinical evidence and rationale to define the potential of HSP27 and HSP90 inhibitors in GBM management.
authors: Department of Clinical Neurological Sciences, Western University, 339 Windermere Road, Suite C7-134, London, ON, N6A 5A5, Canada.
authors: Randy
authors: R
authors: van Ommeren
authors: Department of Clinical Neurological Sciences, Western University, 339 Windermere Road, Suite C7-134, London, ON, N6A 5A5, Canada.
authors: Michael D
authors: MD
authors: Staudt
authors: Department of Clinical Neurological Sciences, Western University, 339 Windermere Road, Suite C7-134, London, ON, N6A 5A5, Canada.
authors: Hu
authors: H
authors: Xu
authors: Department of Clinical Neurological Sciences, Western University, 339 Windermere Road, Suite C7-134, London, ON, N6A 5A5, Canada. mhebb@uwo.ca.
authors: Matthew O
authors: MO
authors: Hebb
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005909:Glioblastoma / Q000188:drug therapy* / Q000378:metabolism; D055551:HSP27 Heat-Shock Proteins / Q000037:antagonists & inhibitors*; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors*; D006801:Humans; D058990:Molecular Targeted Therapy
chemical_list: D000970:Antineoplastic Agents; D055551:HSP27 Heat-Shock Proteins; D018841:HSP90 Heat-Shock Proteins
keywords: Cancer; Gene therapy; Glioma; Heat shock; Molecular chaperones